INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2019

Icosapent ethyl (4 g/day) significantly reduced the risk of major ischemic cardiovascular events in statin-treated patients with elevated triglycerides.

A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).

Study type
Multicenter, randomized, double-blind, placebo-controlled trial
Who was studied
8179 statin-treated patients with established cardiovascular disease or diabetes plus risk factors, and elevated fasting triglycerides
What was measured
Composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina

THE PAPER

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. N Engl J Med, 2019.

PubMed 30415628 ↗DOI 10.1056/nejmoa1812792 ↗

Heart & arteriesDiabetes & blood sugar

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.